Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol in Advanced Non-Small Cell Lung Cancer
NCT03087708Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2018
- Primary completion
- Jan 2021
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of naloxegol in non-small cell lung cancer (NSCLC), opioid-induced constipation (OIC), sponsored by Cancer and Leukemia Group B. Started Mar 2018; status: terminated.
02
Drugs
naloxegol
03
Conditions
non-small cell lung cancer (NSCLC)opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT03087708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087708.